MSD wins full sweep in world’s best-selling drug clash

A PTAB dispute over $29.5bn drug reaches a dramatic conclusion, at a critical time ahead of the drug's US patent expiration.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

5 ways the USPTO director is changing US innovation

24 December 2025 John Squires has rewired the country’s patents system since becoming USPTO director—but which changes are most impactful? Sarah Speight explores.

Americas

Mirum targets generics in quartet of suits over liver treatment

22 December 2025 Biopharma company and two others have taken action against numerous defendants over proposed generic versions of Livmarli, Mirum’s core revenue driver.

Americas

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

22 December 2025 Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.

More features

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

Edwards v Meril: Behind the UPC’s landmark medtech showdown

5 ways the USPTO director is changing US innovation

EU unveils sweeping pharma, biotech, and medical device reforms

Mirum targets generics in quartet of suits over liver treatment

Hogan Lovells and Cadwalader strike historic deal to create $3.6bn firm

WATCH: Enabling success — overcoming §112 in the new era of life sciences patents

MSD wins full sweep in world’s best-selling drug clash

More on this story

Editor's picks

Editor's picks

More features